Clinical Trial

A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

Study acronym: G-LINK

Terminated

View on ClinicalTrials.gov →

Why the trial stopped

Study terminated due to insufficient enrollment.

Summary

The purpose of this study is to assess the effectiveness and safety of guselkumab following a switch from ustekinumab or an ustekinumab biosimilar in participants with moderate to severe psoriasis, a chronic inflammatory skin disease characterized by erythematous, scaly plaques that may be associated with pain and pruritus, in routine clinical practice.

Protocol Amendment History 5 changes

critical Trial terminated 2026-07-28

critical Trial terminated: Study terminated due to insufficient enrollment. 2026-07-28

notable Enrollment reduced: 200 -> 9 participants 2026-07-28

notable Primary completion moved earlier: 2027-03-15 -> 2026-06-29 2026-07-28

minor Completion moved earlier: 2027-09-01 -> 2026-06-29 2026-07-28

Trial Details

NCT Number	NCT07449234
Lead Sponsor	Janssen-Cilag Ltd.
Conditions	Psoriasis
Enrollment	9 participants
Start Date	2026-02-09
Primary Completion	2026-06-29 (estimated)
Study Completion	2026-06-29 (estimated)
Updated on ClinicalTrials.gov	2026-07-27